Hematoxylin as a killer of CALR mutant cancer cells

(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Patients with myeloproliferative neoplasm (MPN) often have a carcinogenic mutated form of the calreticulin gene (CALR). Scientists of the research group of Robert Kralovics, Adjunct Principal Investigator at CeMM and group leader at the Medical University of Vienna, have now identified hematoxylin as a novel CALR inhibitor. The study, published in the renowned journal Blood, shows how hematoxylin compounds affect a...